New gene therapies developed using CRISPR gene editing offer the promise of treating or even curing debilitating diseases.

Three patients are in “safe, deep remission” after receiving a CRISPR-Cas9-modified cell therapy for autoimmune disease ...

Scientists at St. Jude Children's Research Hospital have revealed how Fanzor2's divergence from bacterial ancestors may make ...

Amidst the long-running Cas9 patent battle, Editas Medicine has struck a deal to sell a portion of its future revenue stream ...

Against the backdrop of a Cas9 patent battle that refuses to die, Editas Medicine is cashing in a chunk of the licensing ...

ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, and Université de Montréal (‘UdeM’), a leading Canadian research institution renowned for scientific innovation and technology transfer, ...

Age impedes the ability of the brain’s stem cells to churn out new cells, but the study’s authors found that reducing the ...

The agreement grants the university access to ERS’ CRISPR/Cas9 patent portfolio – including enabling the launch of two CRISPR/Cas9 screening facility platforms at UdeM's Institute for Research ...

Here are some of the most groundbreaking developments in science this week, ranging from a novel approach to rejuvenating ...

As of October 2024, there are more than thirty FDA-approved gene therapies, spanning a diverse array of diseases such as ...